Related Experiment Video
Updated: Apr 30, 2026
Application of Laparoscopic Hepatectomy Combined with Intraoperative Microwave Ablation in Colorectal Cancer Liver Metastasis
Published on: March 3, 2023
MRI-guided laser ablation of neuroendocrine tumor hepatic metastases
Jukka Perälä1, Rauli Klemola2, Raija Kallio3
1Department of Radiology, Oulu University Hospital, Oulu, Finland.
Background:
Neuroendocrine tumors (NET) represent a therapeutically challenging and heterogeneous group of malignancies occurring throughout the body, but mainly in the gastrointestinal system.
Purpose:
To describe magnetic resonance imaging (MRI)-guided laser ablation of NET liver metastases and assess its role within the current treatment options and methods.
Material And Methods:
Two patients with NET tumor hepatic metastases were treated with MRI-guided interstitial laser ablation (LITT). Three tumors were treated. Clinical follow-up time was 10 years.
Results:
Both patients were successfully treated. There were no local recurrences at the ablation site during the follow-up. Both patients had survived at 10-year follow-up. One patient is disease-free.
Conclusion:
MRI-guided laser ablation can be used to treat NET tumor liver metastases but combination therapy and a rigorous follow-up schedule are recommended.
Insights
Magnetic resonance imaging (MRI)-guided laser ablation offers a promising treatment for neuroendocrine tumor (NET) liver metastases. This minimally invasive technique demonstrated successful outcomes and long-term survival in a 10-year follow-up study.
Area of Science:
- Oncology
- Interventional Radiology
- Medical Technology
Background:
- Neuroendocrine tumors (NET) are a diverse and challenging group of cancers, frequently metastasizing to the liver.
- Effective treatment strategies for NET liver metastases are crucial due to their therapeutic complexity.
Observation:
- This study evaluated MRI-guided interstitial laser ablation (LITT) for treating liver metastases in two patients with NET.
- A total of three tumors were treated, with a clinical follow-up period extending to 10 years.
Findings:
- Both patients achieved successful treatment outcomes with MRI-guided LITT.
- No local tumor recurrences were observed at the ablation sites during the 10-year follow-up period.
- Both patients survived the 10-year follow-up, with one patient remaining disease-free.
Implications:
- MRI-guided laser ablation is a viable option for managing NET liver metastases.
- Combination therapy and stringent follow-up protocols are recommended for optimal patient management.
- This technique offers a minimally invasive approach with potential for long-term disease control.
